In June 2017 The FDA Announced It Is Evaluating Possible Drug Label Changes And The Need For Other Regulatory Actions
(Posted by Tom Lamb at DrugInjuryWatch.com)
According to the document "Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS): January - March 2017", the FDA is evaluating the extent of ocular toxicities including vision loss and retinal detachment associated with Keytruda (pembrolizumab), Opdivo (nivolumab), and Yervoy (ipilimumab).
More information about this developing drug safety issue is presented in this news report, "FDA Considers Label Changes for Keytruda, Opdivo and Yervoy", which was posted July 12, 2017 on the Regulatory Affairs Professional Society (RAPS) website.
Here are some contextual details provided by reporter Zachary Brennan in this article:
The consideration for changing the labels of Yervoy, Opdivo and Keytruda comes as FDA says it has completed post-marketing reviews for sight-threatening complications such as retinal detachment and vision loss with the three treatments.
Tralisa Colby, an FDA public affairs specialist, explained to Focus: "Regulatory discussions are ongoing regarding PD-1 pathway blocking antibodies in attempts to improve the consistency and effectiveness of the information regarding immune-mediated ARs provided in the labels. Those labeling changes may include additional characterization of ocular inflammatory conditions; however, the current term, uveitis, should convey the severity and potential ocular complications to oncology physicians."
Keytruda / Opdivo / Yervoy
Free Case Evaluation
Strictly Confidential, No Obligation.
Further, this July 12 RAPS news report states that the Prescribing Information documents, or drug labels, for Yervoy, Opdivo, and Keytruda have uveitis listed as a potential immune-mediated adverse reaction (AR).
Of course, we will continue to monitor the safety profile of Yervoy, Opdivo, and Keytruda, with special attention to any label changes mandated by the FDA as regards retinal detachment and/or vision loss.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review done by attorney Tom Lamb)